Use this button to switch between dark and light mode.

Minimize Risks to Special Populations in Clinical Trials

September 20, 2022

Advise healthcare clients on key regulatory and compliance considerations for clinical trials involving so-called special populations of research subjects like pregnant women, human fetuses, neonates, prisoners, and children. Understand how the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) set standards to protect these populations from undue influence when serving as research subjects in clinical trials.

Read Now »


Related Content

  • Master Clinical Trial Agreement
    Use this template to expedite negotiating and drafting an agreement between a drug or medical device manufacturer (sponsor) and a healthcare institution taking on responsibility for conducting a clinical trial on behalf of the sponsor.
  • Informed Consent for Clinical Trials Form
    Build your trial-specific participant consent form with this basic template used to provide clinical trial participants required sufficient information to make an effective consent to participate in a study. The template includes practical guidance, drafting notes, and optional clauses.
  • Right-to-Try and Expanded Access to Experimental Drugs Checklist
    Rely on this checklist to ensure your healthcare clients comply with right-to-try and expanded access provisions of the 21st Century Cures Act and the Right to Try Act of 2018 when providing medications to ill patients not otherwise able to participate in clinical trials.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.   


Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+